221 related articles for article (PubMed ID: 9119154)
1. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
Lubiniecki AS; McAllister PR; Smith TM; Shadle PJ
Dev Biol Stand; 1996; 88():309-15. PubMed ID: 9119154
[No Abstract] [Full Text] [Related]
2. Viral safety of biological products and the concept of validation.
Horaud F
Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
[No Abstract] [Full Text] [Related]
3. Relationship between nature and source of risk and process validation.
Berthold W; Werz W; Walter JK
Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
[No Abstract] [Full Text] [Related]
4. Future development of harmonized guidelines.
Hayakawa T
Dev Biol Stand; 1996; 88():331-2. PubMed ID: 9119158
[No Abstract] [Full Text] [Related]
5. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
[No Abstract] [Full Text] [Related]
6. Use of a statistical strategy to evaluate sources of variability in viral safety experiments for a recombinant biopharmaceutical.
McAllister PR; Shadle PJ; Smith TM; Scott RG; Lubiniecki AS
Dev Biol Stand; 1996; 88():111-21. PubMed ID: 9119122
[No Abstract] [Full Text] [Related]
7. Virus inactivation of fresh plasma.
Mohr H
Vox Sang; 1998; 74 Suppl 2():171-2. PubMed ID: 9704442
[No Abstract] [Full Text] [Related]
8. Evaluation of anti-viral filters.
Hughes B; Bradburne A; Sheppard A; Young D
Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
[TBL] [Abstract][Full Text] [Related]
9. Validation of virus removal in large scale purification processes.
Fritsch E
Dev Biol Stand; 1992; 76():239-48. PubMed ID: 1478342
[No Abstract] [Full Text] [Related]
10. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
11. Adventitious agents from animal-derived raw materials--a method of risk assessment.
Foster LG
Dev Biol Stand; 1996; 88():283-90. PubMed ID: 9119152
[TBL] [Abstract][Full Text] [Related]
12. Safety of biopharmaceuticals: a current perspective.
Parkman PD
Dev Biol Stand; 1996; 88():5-7. PubMed ID: 9119163
[TBL] [Abstract][Full Text] [Related]
13. Biologicals: an attempt at classification and its implication for the viral safety of products.
Horaud F
Dev Biol Stand; 1993; 81():17-24. PubMed ID: 8174800
[No Abstract] [Full Text] [Related]
14. Safety of biological products prepared from mammalian cell culture. DNA.
Dev Biol Stand; 1998; 93():136-8. PubMed ID: 9737393
[No Abstract] [Full Text] [Related]
15. Safety of biological products prepared from mammalian cell culture. Host-cell proteins.
Dev Biol Stand; 1998; 93():139-40. PubMed ID: 9737394
[No Abstract] [Full Text] [Related]
16. Strategies for the validation of viral inactivation in biologic products.
Aronson DL
Prog Clin Biol Res; 1990; 324():137-49. PubMed ID: 2408050
[No Abstract] [Full Text] [Related]
17. Viral safety of biological products in WHO policy.
Grachev VP
Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628
[TBL] [Abstract][Full Text] [Related]
18. Virus validation procedures: practical aspects.
Minor PD
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S10-2. PubMed ID: 7495959
[TBL] [Abstract][Full Text] [Related]
19. Viral safety of recombinant factor IX.
Adamson S; Charlebois T; O'Connell B; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
[TBL] [Abstract][Full Text] [Related]
20. Adventitious agent test methods.
Sheets RL
Dev Biol (Basel); 2006; 123():135-45; discussion 183-97. PubMed ID: 16566441
[No Abstract] [Full Text] [Related]
[Next] [New Search]
